Show simple item record

dc.contributor.authorMoynihan, Ray
dc.contributor.authorBero, Lisa
dc.contributor.authorRoss-Degnan, Dennis
dc.contributor.authorHenry, David
dc.contributor.authorLee, Kirby
dc.contributor.authorWatkins, Judy
dc.contributor.authorMah, Connie
dc.contributor.authorSoumerai, Stephen Bertram
dc.date.accessioned2017-05-16T16:37:24Z
dc.date.issued2000
dc.identifier.citationMoynihan, Ray, Lisa Bero, Dennis Ross-Degnan, David Henry, Kirby Lee, Judy Watkins, Connie Mah, and Stephen B. Soumerai. 2000. “Coverage by the News Media of the Benefits and Risks of Medications.” New England Journal of Medicine 342 (22) (June): 1645–1650. doi:10.1056/nejm200006013422206.en_US
dc.identifier.issn0028-4793en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32691994
dc.description.abstractBackground The news media are an important source of information about new medical treatments, but there is concern that some coverage may be in- accurate and overly enthusiastic. Methods We studied coverage by U.S. news media of the benefits and risks of three medications that are used to prevent major diseases. The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease. We analyzed a systematic probability sample of 180 newspaper articles (60 for each drug) and 27 television reports that ap- peared between 1994 and 1998. Results Of the 207 stories, 83 (40 percent) did not report benefits quantitatively. Of the 124 that did, 103 (83 percent) reported relative benefits only, 3 (2 per- cent) absolute benefits only, and 18 (15 percent) both absolute and relative benefits. Of the 207 stories, 98 (47 percent) mentioned potential harm to patients, and only 63 (30 percent) mentioned costs. Of the 170 stories citing an expert or a scientific study, 85 (50 percent) cited at least one expert or study with a financial tie to a manufacturer of the drug that had been disclosed in the scientific literature. These ties were disclosed in only 33 (39 percent) of the 85 stories. Conclusions News-media stories about medications may include inadequate or incomplete information about the benefits, risks, and costs of the drugs as well as the financial ties between study groups or experts and pharmaceutical manufacturers.en_US
dc.language.isoen_USen_US
dc.publisherNew England Journal of Medicine (NEJM/MMS)en_US
dc.relation.isversionofdoi:10.1056/NEJM200006013422206en_US
dash.licenseLAA
dc.titleCoverage by the News Media of the Benefits and Risks of Medicationsen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalNew England Journal of Medicineen_US
dash.depositing.authorSoumerai, Stephen Bertram
dc.date.available2017-05-16T16:37:24Z
dc.identifier.doi10.1056/NEJM200006013422206*
dash.contributor.affiliatedSoumerai, Stephen
dash.contributor.affiliatedRoss-Degnan, Dennis


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record